Development and Applications of Initial Dosage Setting of Cibenzoline in Consideration of the Cases of Adverse Reaction Induced by Cibenzoline on Clinical Services in a Hospital.
Y. Maeda, T. Konishi, K. Omoda, Y. Takeda, H. Fujii, I. Kanazawa, S. Eno, S. Tsukiai
{"title":"Development and Applications of Initial Dosage Setting of Cibenzoline in Consideration of the Cases of Adverse Reaction Induced by Cibenzoline on Clinical Services in a Hospital.","authors":"Y. Maeda, T. Konishi, K. Omoda, Y. Takeda, H. Fujii, I. Kanazawa, S. Eno, S. Tsukiai","doi":"10.5649/JJPHCS1975.26.239","DOIUrl":null,"url":null,"abstract":"Adverse reactions induced by cibenzoline at this hospital showed the trough value of cibenzoline at the time to be above 400ng/mL. In these cases, by adjusting the trough values to 150-230ng/mL and also by reducing the cibenzoline dosage, the effects of cibenzoline could thus be maintained while adverse reactions were avoided. Therefore, the relationship between the trough value based on cibenzoline dosage and the creatinine clearance in 19 cases who took cibenzoline was examined. In order to adjust trough level to 150-250ng/mL as the goal concentration based on the relation formula, the recommended dosage of cibenzoline and the creatinine clearance were calculated. The utility of an initial dosage setting according to the combination a recommended dosage of cibenzoline and the creatinine clearance nomogram reported by Nielsen et al. was examined in 9 cases.As a result, using this nomogram, the percentage of the goal concentration thus significantly increased, while the percentage of hypoglycemia significantly decreased. Accordingly, the nomogram of cibenzoline prepared in our hospital was thus concluded to be clinically acceptable.","PeriodicalId":14621,"journal":{"name":"Japanese Journal of Hospital Pharmacy","volume":"38 1","pages":"239-249"},"PeriodicalIF":0.0000,"publicationDate":"2000-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Hospital Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5649/JJPHCS1975.26.239","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
Adverse reactions induced by cibenzoline at this hospital showed the trough value of cibenzoline at the time to be above 400ng/mL. In these cases, by adjusting the trough values to 150-230ng/mL and also by reducing the cibenzoline dosage, the effects of cibenzoline could thus be maintained while adverse reactions were avoided. Therefore, the relationship between the trough value based on cibenzoline dosage and the creatinine clearance in 19 cases who took cibenzoline was examined. In order to adjust trough level to 150-250ng/mL as the goal concentration based on the relation formula, the recommended dosage of cibenzoline and the creatinine clearance were calculated. The utility of an initial dosage setting according to the combination a recommended dosage of cibenzoline and the creatinine clearance nomogram reported by Nielsen et al. was examined in 9 cases.As a result, using this nomogram, the percentage of the goal concentration thus significantly increased, while the percentage of hypoglycemia significantly decreased. Accordingly, the nomogram of cibenzoline prepared in our hospital was thus concluded to be clinically acceptable.